Phase II study of temozolomide plus pegylated interferon‐α‐2b for metastatic melanoma
Wen‐Jen Hwu(The University of Texas MD Anderson Cancer Center), Alan N. Houghton(Eastern Cooperative Oncology Group), Lynne Lamb(Memorial Sloan Kettering Cancer Center), Philip O. Livingston(Memorial Sloan Kettering Cancer Center), Suzan Aird(Memorial Sloan Kettering Cancer Center), Katherine S. Panageas(Mayo Clinic), Jedd D. Wolchok(Cornell University), Linda Williams(Edinburgh Cancer Research), Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Susan E. Krown(Memorial Sloan Kettering Cancer Center), Jennifer H. Menell
Cited by 49
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k